News Sentiment

PLRZ sentiment intelligence

Polyrizon Ltd. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 60 Balanced news tone 46 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.65 Week of 10 Jul 2026
Weighted tone 60/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

72/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+6.2% over one week, +31.6% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

[6-K] Polyrizon Ltd. Current Report (Foreign Issuer) | PLRZ SEC Filing - Form 6-K

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 72/100 classification
One-week reaction 6.2% Price confirming higher
Trend fit Trend active 31.6% over four weeks
Fair value -96.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 21
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 7
TradingView 5
TradingKey 5
Investing.com 4
GlobeNewswire 3
MT Newswires 3
The Manila Times 3

Event Lens

What the news is about

Classified themes
Earnings 17
Market update 15
Regulatory and legal 8
Analyst action 3
Guidance 1
Deals and strategy 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-46 of 46
Investing.com Direct company coverage

Polyrizon initiates nasal residence time study for allergy blocker

Polyrizon Ltd. (NASDAQ:PLRZ) has commenced a human study to evaluate the nasal residence time of its NASARIX allergy blocker product, marking a key clinical development milestone. This study aims to support regulatory submissions, including with the U.S. FDA, by assessing how lon

Tone
Negative 37/100
Event
Regulatory and legal
Published
15 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

How long can a nasal allergy blocker stay put? New human study aims to find out

Polyrizon (Nasdaq: PLRZ) has signed agreements with a leading European university medical center and a specialized CRO to conduct a human study for NASARIX™ (PL-14) Allergy Blocker. The study will measure nasal residence time to determine the duration of the product's protective

Tone
Positive 66/100
Event
Market update
Published
15 Jun 2026 11:39
Source
Stock Titan